Member News

Cambridge Research Biochemicals Signs Licensing Deal with The Scripps Research Institute for ‘Click’ Chemistry

Cleveland, UK: Leading research peptide manufacturer Cambridge Research Biochemicals (CRB) announced today that it has signed a non-exclusive license with The Scripps Research Institute (TSRI) to add click chemistry services, namely the “click” labelling of peptides and proteins, to its existing service portfolio.

CRB is a world leader in providing complex and heavily modified peptides to researchers within the Life Sciences discipline. The partnership with TSRI will enable the company to synthesise more creative and complex peptide targets utilising click chemistry, particularly those considered to be of high importance in the field of drug discovery.
(Continue reading)

« Return to Table of Contents

Otonomy Enrolls First Meniere's Disease Patients in OTO-104 Multiple-Dose Safety Study

SAN DIEGO, Oct. 9, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the enrollment of the first patients in a multiple-dose safety study of OTO-104 initiated in the United Kingdom (U.K.) in patients with Ménière's disease.

The prospective, randomized, placebo-controlled study, designed to evaluate the safety of multiple doses of OTO-104, will enroll 125 patients across multiple trial sites in the U.K. In the first part of the study, patients will be randomized to receive two doses of either placebo or 12 mg OTO-104 by intratympanic (IT) injection given at three month intervals. Patients completing the double-blind portion of the study will be eligible to participate in an open-label extension study where all patients will receive two IT injections of OTO-104 at three month intervals.

(Continue reading)

« Return to Table of Contents

Curtana Pharmaceuticals Awarded NIH Small Business Technology Transfer Grant to Advance Glioblastoma Cancer Therapy

Curtana Pharmaceuticals, a privately-held, preclinical stage pharmaceutical company developing the first targeted small molecule therapeutics for glioblastoma (GBM) and other brain cancers, announced today that it has been awarded $225,000 by the National Cancer Institute of the National Institutes of Health (NIH) through the Small Business Technology Transfer (STTR) program.  The STTR grant follows closely on the heels of a $7.6 million product development grant funded by the Cancer Prevention and Research Institute of Texas (CPRIT).

Collaborating with Curtana on the STTR grant as Principal Investigator is Professor Santosh Kesari, Director of Neuro-Oncology at Moores Cancer Center, University of California, San Diego and co-founder of Curtana whose research, utilizing a novel combined pharmacophore-based small molecule design methodology, has discovered several candidate compounds.

(Continue reading)

« Return to Table of Contents

Fostering Innovation and STEM Leadership in an Era of Globalization

On October 24, 2014 at 8:30AM, UCSD will host the Department of Commerce Buereau of Industry and Security (BIS) Emerging Technology and Research Advisory Committee (ETRAC) public meeting at the San Diego Supercomputer Center Auditorium.

Topic: Fostering Innovation and STEM Leadership in an Era of Globalization

Attendees will have a valuable opportunity to participate in a public dialogue on emerging technology and research and export controls. For a preview of the session, click here.

For more information on the session, click here.

« Return to Table of Contents

FDA Approves NeuroGenetic Pharmaceuticals Application To Begin Clinical Trials for Alzheimer's Treatment and Prevention

The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application from NeuroGenetic Pharmaceuticals, Inc. (NGP) to begin clinical trials on its NGP 555 compound to treat and prevent Alzheimer’s disease (AD). The approval follows successful completion of all preclinical phases under a fast-track grant from the National Institute of  Neurologic Disease and Stroke (NINDS).

Dr. William T. Comer, CEO of NGP, a privately held biopharmaceutical company focused on Alzheimer’s disease therapeutics, said NGP completed pre-clinical toxicology and safety studies of NGP 555 under Small Business Innovation Research (SBIR) grants from the NINDS, grant no.  1U44NS073133-01A1  totaling $3.4 million. The efficacy studies showed beneficial and chronic effects on amyloid biomarkers, pathology, and cognition while lacking the side effects of other compounds and mechanisms for preventing Alzheimer’s disease (AD).

(Continue reading)

« Return to Table of Contents

Working Mother names Scripps Health a Top Company

Scripps recognized for 10th consecutive year for its family-friendly culture

Working Mother magazine has named Scripps Health as one of the 2014 Working Mother 100 Best Companies for outstanding leadership in establishing policies, programs and corporate culture that supports working moms.

“We’re honored to be among the great companies on Working Mother’s list for the 10th consecutive year,” said Chris Van Gorder, president and CEO of Scripps Health. “We believe in fostering a culture of workplace excellence that provides flexibility and opportunities for all of our employees. That way, they can be at their best and provide exceptional care to our patients.”

(Continue reading)

« Return to Table of Contents